Natco Pharma ties up with Gilead
According to a press release Natco Pharma Limited has signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker’s chronic hepatitis C medicines.
Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a release.
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
